Is MIST or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% NanoViricides N/A -87.90% -78.69%

Is NNVC or HUMA more profitable?

NanoViricides has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. NanoViricides' return on equity of -87.90% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Humacyte -4,836.06% -2,914.18% -89.45%

Does the media refer more to NNVC or HUMA?

In the previous week, Humacyte had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Humacyte and 1 mentions for NanoViricides. Humacyte's average media sentiment score of 0.48 beat NanoViricides' score of -0.20 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NGEN or NNVC?

NervGen Pharma is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A -$0.09 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is NGEN or NNVC more profitable?

NervGen Pharma's return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Does the media prefer NGEN or NNVC?

In the previous week, NervGen Pharma had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for NervGen Pharma and 1 mentions for NanoViricides. NervGen Pharma's average media sentiment score of 0.62 beat NanoViricides' score of -0.20 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, HURA or NNVC?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is HURA or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% NanoViricides N/A -87.90% -78.69%

Does the media prefer HURA or NNVC?

In the previous week, TuHURA Biosciences had 4 more articles in the media than NanoViricides. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for NanoViricides. TuHURA Biosciences' average media sentiment score of 0.94 beat NanoViricides' score of -0.20 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PYXS or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% NanoViricides N/A -87.90% -78.69%

Does the media favor PYXS or NNVC?

In the previous week, Pyxis Oncology had 3 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Pyxis Oncology and 1 mentions for NanoViricides. Pyxis Oncology's average media sentiment score of 0.80 beat NanoViricides' score of -0.20 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

NanoViricides (NNVC) Competitors

$1.48 -0.05 (-3.27%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.53 +0.05 (+3.38%)

As of 07/24/2026 07:34 PM Eastern

Compare

NNVC vs. MIST, HUMA, NGEN, HURA, and PYXS

Should you buy NanoViricides stock or one of its competitors? MarketBeat compares NanoViricides with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NanoViricides include Milestone Pharmaceuticals (MIST), Humacyte (HUMA), NervGen Pharma (NGEN), TuHURA Biosciences (HURA), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry.

How does NanoViricides compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

NanoViricides has lower revenue, but higher earnings than Milestone Pharmaceuticals. NanoViricides is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.78M	80.95	-$63.06M	-$0.68	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Milestone Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 1 articles in the media. Milestone Pharmaceuticals' average media sentiment score of 1.87 beat NanoViricides' score of -0.20 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Very Positive
NanoViricides	Neutral

NanoViricides' return on equity of -87.90% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
NanoViricides	N/A	-87.90%	-78.69%

Milestone Pharmaceuticals presently has a consensus price target of $7.25, suggesting a potential upside of 525.00%. NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 305.41%. Given Milestone Pharmaceuticals' higher probable upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Milestone Pharmaceuticals beats NanoViricides on 9 of the 14 factors compared between the two stocks.

How does NanoViricides compare to Humacyte?

NanoViricides (NYSE:NNVC) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Humacyte had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Humacyte and 1 mentions for NanoViricides. Humacyte's average media sentiment score of 0.48 beat NanoViricides' score of -0.20 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides presently has a consensus price target of $6.00, indicating a potential upside of 305.41%. Humacyte has a consensus price target of $6.25, indicating a potential upside of 900.32%. Given Humacyte's higher possible upside, analysts plainly believe Humacyte is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

NanoViricides has higher earnings, but lower revenue than Humacyte. NanoViricides is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Humacyte	$2.04M	68.00	-$40.83M	-$0.57	N/A

NanoViricides has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. NanoViricides' return on equity of -87.90% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NanoViricides has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market.

Summary

Humacyte beats NanoViricides on 8 of the 15 factors compared between the two stocks.

How does NanoViricides compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and NanoViricides (NYSE:NNVC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, NervGen Pharma had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for NervGen Pharma and 1 mentions for NanoViricides. NervGen Pharma's average media sentiment score of 0.62 beat NanoViricides' score of -0.20 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.3% of NanoViricides shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NervGen Pharma is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NervGen Pharma's return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

NervGen Pharma presently has a consensus target price of $14.00, suggesting a potential upside of 758.90%. NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 305.41%. Given NervGen Pharma's higher possible upside, equities research analysts clearly believe NervGen Pharma is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

NervGen Pharma beats NanoViricides on 8 of the 11 factors compared between the two stocks.

How does NanoViricides compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, TuHURA Biosciences had 4 more articles in the media than NanoViricides. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for NanoViricides. TuHURA Biosciences' average media sentiment score of 0.94 beat NanoViricides' score of -0.20 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 326.54%. NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 305.41%. Given TuHURA Biosciences' higher probable upside, equities research analysts clearly believe TuHURA Biosciences is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

NanoViricides' return on equity of -87.90% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
NanoViricides	N/A	-87.90%	-78.69%

TuHURA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Summary

NanoViricides beats TuHURA Biosciences on 8 of the 13 factors compared between the two stocks.

How does NanoViricides compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NanoViricides' return on equity of -87.90% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
NanoViricides	N/A	-87.90%	-78.69%

NanoViricides has lower revenue, but higher earnings than Pyxis Oncology. NanoViricides is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	11.93	-$79.62M	-$1.31	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, Pyxis Oncology had 3 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Pyxis Oncology and 1 mentions for NanoViricides. Pyxis Oncology's average media sentiment score of 0.80 beat NanoViricides' score of -0.20 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Pyxis Oncology presently has a consensus target price of $6.86, suggesting a potential upside of 162.73%. NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 305.41%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Pyxis Oncology and NanoViricides tied by winning 7 of the 14 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$34.02M	$966.60M	$6.88B	$23.46B
Dividend Yield	N/A	4.84%	2.67%	4.20%
P/E Ratio	-2.06	1.53	27.00	30.72
Price / Sales	N/A	109.08	491.80	80.46
Price / Cash	N/A	20.06	50.54	31.69
Price / Book	2.24	8.48	10.28	4.73
Net Income	-$8.29M	-$3.23M	$3.60B	$1.07B
7 Day Performance	-15.43%	-2.80%	-1.25%	-0.44%
1 Month Performance	13.85%	-4.40%	-0.35%	0.73%
1 Year Performance	-11.90%	28.83%	18.41%	14.12%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	1.6512 of 5 stars	$1.48 -3.3%	$6.00 +305.4%	-13.5%	$34.02M	N/A	N/A	20
MIST Milestone Pharmaceuticals	2.2445 of 5 stars	$1.23 +4.2%	$7.25 +489.4%	-26.1%	$146.91M	$1.55M	N/A	30	Positive News
HUMA Humacyte	3.4187 of 5 stars	$0.67 +2.2%	$6.25 +831.7%	-76.6%	$145.69M	$2.04M	N/A	150
NGEN NervGen Pharma	2.3429 of 5 stars	$1.78 +2.9%	$14.00 +686.5%	N/A	$143.52M	N/A	N/A	N/A	Analyst Forecast
HURA TuHURA Biosciences	2.1789 of 5 stars	$2.21 -1.3%	$9.00 +307.2%	-25.7%	$142.65M	N/A	N/A	N/A	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. MIST, HUMA, NGEN, HURA, and PYXS

How does NanoViricides compare to Milestone Pharmaceuticals?

Summary

How does NanoViricides compare to Humacyte?

Summary

How does NanoViricides compare to NervGen Pharma?

Summary

How does NanoViricides compare to TuHURA Biosciences?

Summary

How does NanoViricides compare to Pyxis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. MIST, HUMA, NGEN, HURA, and PYXS

How does NanoViricides compare to Milestone Pharmaceuticals?

Which has stronger valuation and earnings, MIST or NNVC?

Which has more risk & volatility, MIST or NNVC?

Do institutionals & insiders have more ownership in MIST or NNVC?

Does the media refer more to MIST or NNVC?

Is MIST or NNVC more profitable?

Do analysts rate MIST or NNVC?

Summary

How does NanoViricides compare to Humacyte?

Does the media refer more to NNVC or HUMA?

Do analysts prefer NNVC or HUMA?

Which has better valuation & earnings, NNVC or HUMA?

Is NNVC or HUMA more profitable?

Do insiders & institutionals believe in NNVC or HUMA?

Which has more risk and volatility, NNVC or HUMA?

Summary

How does NanoViricides compare to NervGen Pharma?

Does the media prefer NGEN or NNVC?

Do insiders and institutionals hold more shares of NGEN or NNVC?

Which has better earnings and valuation, NGEN or NNVC?

Is NGEN or NNVC more profitable?

Do analysts prefer NGEN or NNVC?

Summary

How does NanoViricides compare to TuHURA Biosciences?

Does the media prefer HURA or NNVC?

Do insiders & institutionals hold more shares of HURA or NNVC?

Do analysts recommend HURA or NNVC?

Is HURA or NNVC more profitable?

Which has more volatility and risk, HURA or NNVC?

Which has better earnings & valuation, HURA or NNVC?

Summary

How does NanoViricides compare to Pyxis Oncology?

Do institutionals and insiders hold more shares of PYXS or NNVC?

Is PYXS or NNVC more profitable?

Which has higher earnings and valuation, PYXS or NNVC?

Does the media favor PYXS or NNVC?

Which has more risk & volatility, PYXS or NNVC?

Do analysts recommend PYXS or NNVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools